A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Trial Profile

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs LN 144 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 06 Jun 2017 Preliminary results (n=9) from cohort 1, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Additional data from 16 patients enrolled in the first cohort were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting according to a Lion Biotechnologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top